Skip to main content
. 2017 Jan 16;8(8):12983–13002. doi: 10.18632/oncotarget.14677

Figure 4. Kaplan-Meier curves for patients with different clinicopathological characteristics according to PHD3 expression level in TAMs.

Figure 4

(A) Prognosis of the patients with a single tumor. OS 43.732% in PHD3(–) vs. 70.595% in PHD3(+), p = 0.0516. RR 74.432% in PHD3(–) vs. 48.583% in PHD3(+), p = 0.0054. (B) Prognosis of the patients with tumor size > 5 cm. OS 35.622% in PHD3(–) vs. 60.577% in PHD3(+), p = 0.1900. RR 83.750% in PHD3(–) vs. 60.921% in PHD3(+), p = 0.0338. (C) Prognosis of the patients with HBV (+). OS 40.071% in PHD3(–) vs. 69.020% in PHD3(+), p = 0.0343. RR 82.692% in PHD3(–) vs. 57.358% in PHD3(+), p = 0.0106. (D) Prognosis of the patients with AFP ≤ 20 μg/l. OS 30.000% in PHD3(–) vs. 80.000% in PHD3(+), p = 0.1703. RR 100.000% in PHD3(–) vs. 20.455% in PHD3(+), p = 0.0007. (E) Prognosis of the patients with Edmondson stage I–II. OS 44.318% in PHD3(–) vs. 69.347% in PHD3(+), p = 0.0485. RR 77.143% in PHD3(–) vs. 51.302% in PHD3(+), p = 0.0108. (F) Prognosis of the patients with BCLC 0+A. OS 56.643% in PHD3(–) vs. 76.103% in PHD3(+), p = 0.0596. RR 64.835% in PHD3(–) vs. 41.791% in PHD3(+), p = 0.0463. Log-rank test was used.